Genetic variants in pigment epithelium-derived factor influence response of polypoidal choroidal vasculopathy to photodynamic therapy.

[1]  J. Slakter,et al.  TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY WITH PHOTODYNAMIC THERAPY , 2012, Retina.

[2]  K. Matsuo,et al.  Joint effect of cigarette smoking and CFH and LOC387715/HTRA1 polymorphisms on polypoidal choroidal vasculopathy. , 2010, Investigative ophthalmology & visual science.

[3]  D. Podzamczer,et al.  Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients , 2010, AIDS.

[4]  Y. Tano,et al.  One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. , 2010, Ophthalmology.

[5]  Augustinus Laude,et al.  Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: Same or different disease? , 2010, Progress in Retinal and Eye Research.

[6]  I. Constable,et al.  Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration. , 2009, Ophthalmology.

[7]  L. Carey,et al.  Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy. , 2009, Seminars in radiation oncology.

[8]  H. Yamashita,et al.  TWO-YEAR VISUAL OUTCOMES AFTER PHOTODYNAMIC THERAPY IN AGE-RELATED MACULAR DEGENERATION PATIENTS WITH OR WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY LESIONS , 2009, Retina.

[9]  R. Yamada,et al.  ARMS2 (LOC387715) variants in Japanese patients with exudative age-related macular degeneration and polypoidal choroidal vasculopathy. , 2009, American journal of ophthalmology.

[10]  M. Daly,et al.  Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. , 2009, Investigative ophthalmology & visual science.

[11]  M. Mandai,et al.  Recurrence of polypoidal choroidal vasculopathy after photodynamic therapy , 2008, Japanese Journal of Ophthalmology.

[12]  A. Tsujikawa,et al.  Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy. , 2008, American journal of ophthalmology.

[13]  R. Yamada,et al.  Correlation between CFH Y402H and HTRA1 rs11200638 genotype to typical exudative age‐related macular degeneration and polypoidal choroidal vasculopathy phenotype in the Japanese population , 2008, Clinical & experimental ophthalmology.

[14]  I. Bhutto,et al.  Reduction of endogenous angiogenesis inhibitors in Bruch's membrane of the submacular region in eyes with age-related macular degeneration. , 2008, Archives of ophthalmology.

[15]  Y. Tano.  Guidelines for PDT in Japan. , 2008, Ophthalmology.

[16]  N. Hamajima,et al.  Elevated C-reactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular age-related macular degeneration. , 2007, Ophthalmology.

[17]  I. Maruko,et al.  Clinical characteristics of exudative age-related macular degeneration in Japanese patients. , 2007, American journal of ophthalmology.

[18]  A. Tsujikawa,et al.  Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy. , 2007, American journal of ophthalmology.

[19]  M. Mandai,et al.  HEMORRHAGIC COMPLICATIONS AFTER PHOTODYNAMIC THERAPY FOR POLYPOIDAL CHOROIDAL VASCULOPATHY , 2007, Retina.

[20]  M. Kase,et al.  Positive association of pigment epithelium-derived factor with total antioxidant capacity in the vitreous fluid of patients with proliferative diabetic retinopathy , 2007, British Journal of Ophthalmology.

[21]  A. Majji,et al.  Ultrasonographic characteristics and treatment outcomes of surgery for vitreous hemorrhage in idiopathic polypoidal choroidal vasculopathy. , 2006, American journal of ophthalmology.

[22]  R. Obata,et al.  Triamcinolone acetonide suppresses early proangiogenic response in retinal pigment epithelial cells after photodynamic therapy in vitro , 2006, British Journal of Ophthalmology.

[23]  K. Bartz-Schmidt,et al.  Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. , 2006, American journal of ophthalmology.

[24]  Y. Hirami,et al.  Recurrent bleeding after photodynamic therapy in polypoidal choroidal vasculopathy. , 2006, American journal of ophthalmology.

[25]  P. Campochiaro,et al.  Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. , 2006, Human gene therapy.

[26]  J. Ott,et al.  Complement Factor H Polymorphism in Age-Related Macular Degeneration , 2005, Science.

[27]  L. Arias,et al.  Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age related macular degeneration , 2005, British Journal of Ophthalmology.

[28]  S. Yoneya,et al.  Intraocular gene transfer of pigment epithelium‐derived factor rescues photoreceptors from light‐induced cell death , 2005, Journal of cellular physiology.

[29]  M. Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[30]  T. Lai,et al.  Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. , 2004, Ophthalmology.

[31]  N. Yoshimura,et al.  Apolipoprotein E polymorphisms in Japanese patients with polypoidal choroidal vasculopathy and exudative age-related macular degeneration. , 2004, American journal of ophthalmology.

[32]  U. Schmidt-Erfurth,et al.  Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. , 2003, Investigative ophthalmology & visual science.

[33]  M. Matsumura,et al.  Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. , 2003, Archives of ophthalmology.

[34]  M. Blumenkranz,et al.  Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. , 2002, Archives of ophthalmology.

[35]  O. Volpert,et al.  Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. , 2002, American journal of ophthalmology.

[36]  P. Campochiaro,et al.  AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. , 2002, Investigative ophthalmology & visual science.

[37]  P. Campochiaro,et al.  Pigment epithelium‐derived factor inhibits retinal and choroidal neovascularization , 2001, Journal of cellular physiology.

[38]  Simon P. Harding,et al.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. , 2001, American journal of ophthalmology.

[39]  W. Benedict,et al.  Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. , 1999, Science.

[40]  W. Willett,et al.  A prospective study of cigarette smoking and age-related macular degeneration in women. , 1996, JAMA.

[41]  R J Glynn,et al.  A prospective study of cigarette smoking and risk of age-related macular degeneration in men. , 1996, JAMA.

[42]  J. Tombran-Tink,et al.  PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. , 1991, Experimental eye research.

[43]  F L Ferris,et al.  Senile macular degeneration: a case-control study. , 1983, American journal of epidemiology.

[44]  P. Tommila,et al.  Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration. , 2010, Ophthalmology.

[45]  D. S. Mcleod,et al.  Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. , 2006, Experimental eye research.

[46]  L. Yannuzzi,et al.  Polypoidal choroidal vasculopathy. , 2004, Survey of ophthalmology.

[47]  S. Harding.  Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials¿TAP Report No. 5 , 2002 .

[48]  Neil M Bressler,et al.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. , 2002, American journal of ophthalmology.

[49]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[50]  N. Bressler,et al.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. , 1999, Archives of ophthalmology.